Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
03 Abril 2024 - 9:00AM
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage
oncology company developing MasterKey therapies that target
families of oncogenic mutations in patients with cancer, today
announced its participation in upcoming investor conferences.
Presentation details with President and Chief Executive Officer,
Mark Velleca, M.D., Ph.D., are as follows:
-
23rd Annual Needham Virtual Healthcare Conference presentation at
8:00am ET on Wednesday, April 10, 2024
-
Stifel Virtual Targeted Oncology Forum fireside chat at 10:00am ET
on Tuesday, April 16, 2024
-
Piper Sandler Spring Biopharma Symposium on Wednesday, April 17,
2024, in Boston, Mass.
Webcasts will be available at the start of the
presentations on the investor relations section of the Company’s
website, www.blackdiamondtherapeutics.com. Replays of the
presentations will also be available and archived on the site for
90 days.
About Black Diamond
Therapeutics
Black Diamond Therapeutics is a clinical-stage
oncology company focused on the development of MasterKey therapies
that address families of oncogenic mutations in clinically
validated targets. The Company’s MasterKey therapies are designed
to address broad genetically defined patient populations, overcome
resistance, minimize wild-type mediated toxicities, and be brain
penetrant to treat CNS disease. The Company is advancing two
clinical-stage programs: BDTX-1535, a brain-penetrant
fourth-generation EGFR MasterKey inhibitor targeting EGFR mutant
NSCLC and GBM, and BDTX-4933, a brain-penetrant RAF MasterKey
inhibitor targeting KRAS, NRAS and BRAF alterations in solid
tumors. For more information, please visit
www.blackdiamondtherapeutics.com
Contacts
For Investors:Mario Corso, Head of Investor
Relations, Black Diamond Therapeuticsmcorso@bdtx.com
For Media:media@bdtx.com
Black Diamond Therapeutics (NASDAQ:BDTX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Black Diamond Therapeutics (NASDAQ:BDTX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024